Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 99 articles:
HTML format
Text format



Single Articles


    June 2018
  1. SAKAMOTO S
    Editorial Comment to Epidemiology of prostate cancer in Asian countries.
    Int J Urol. 2018;25:531-532.
    PubMed     Text format    


    May 2018
  2. YANO A, Arai Y, Kitayama S, Otsuka Y, et al
    Effect of zoledronic acid dosing every 3 months in patients with prostate cancer with skeletal metastases: A multicenter prospective exploratory study with matched historical controls.
    Int J Urol. 2018 May 14. doi: 10.1111/iju.13703.
    PubMed     Text format    


  3. CHEN PY, Chiang PH, Liu YY, Chuang YC, et al
    Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence.
    Int J Urol. 2018 May 13. doi: 10.1111/iju.13581.
    PubMed     Text format     Abstract available


  4. KIMURA T, Egawa S
    Epidemiology of prostate cancer in Asian countries.
    Int J Urol. 2018 May 8. doi: 10.1111/iju.13593.
    PubMed     Text format     Abstract available


  5. SAKAMOTO S
    Editorial Comment to Local treatment for metastatic prostate cancer: A systematic review.
    Int J Urol. 2018;25:403-404.
    PubMed     Text format    


    April 2018
  6. MITSUI Y
    Editorial Comment to Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Sca
    Int J Urol. 2018 Apr 16. doi: 10.1111/iju.13582.
    PubMed     Text format    


  7. MEARINI L
    Editorial Comment to Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13575.
    PubMed     Text format    


  8. KITAGAWA Y
    Editorial Comment to Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13578.
    PubMed     Text format    


  9. IZUMI K
    Editorial Comment to Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13572.
    PubMed     Text format    


  10. TAKAMOTO A, Tanimoto R, Bekku K, Araki M, et al
    Oncological impact of neoadjuvant hormonal therapy on permanent iodine-125 seed brachytherapy in patients with low- and intermediate-risk prostate cancer.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13555.
    PubMed     Text format     Abstract available


  11. NAKAJIMA K, Kaneko G, Takahashi S, Matsuyama H, et al
    Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI)
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13556.
    PubMed     Text format     Abstract available


  12. HASHIMOTO T, Ohori M, Shimodaira K, Kaburaki N, et al
    Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer.
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13563.
    PubMed     Text format     Abstract available


  13. BIANCHI L, Schiavina R, Borghesi M, Bianchi FM, et al
    Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database.
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13565.
    PubMed     Text format     Abstract available


    March 2018
  14. OKIHARA K
    Editorial Comment to Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy.
    Int J Urol. 2018 Mar 25. doi: 10.1111/iju.13570.
    PubMed     Text format    


  15. TILKI D, Pompe RS, Bandini M, Marchioni M, et al
    Local treatment for metastatic prostate cancer: A systematic review.
    Int J Urol. 2018 Mar 23. doi: 10.1111/iju.13535.
    PubMed     Text format     Abstract available


  16. HAKARIYA T, Shida Y, Tsurusaki T, Watanabe J, et al
    Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men.
    Int J Urol. 2018 Mar 8. doi: 10.1111/iju.13542.
    PubMed     Text format     Abstract available


  17. ALBERTS AR, Roobol MJ
    Editorial Comment to Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
    Int J Urol. 2018;25:277.
    PubMed     Text format    


    February 2018
  18. KIKKAWA K, Iba A, Kohjimoto Y, Noda Y, et al
    Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy.
    Int J Urol. 2018 Feb 4. doi: 10.1111/iju.13530.
    PubMed     Text format     Abstract available


  19. AKAMATSU S, Inoue T, Ogawa O, Gleave ME, et al
    Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
    Int J Urol. 2018 Feb 3. doi: 10.1111/iju.13526.
    PubMed     Text format     Abstract available


    January 2018
  20. BEGEMANN D, Anastos H, Kyprianou N
    Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Int J Urol. 2018 Jan 17. doi: 10.1111/iju.13505.
    PubMed     Text format     Abstract available


  21. SAKAMOTO S
    Editorial Comment to Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Int J Urol. 2018 Jan 17. doi: 10.1111/iju.13510.
    PubMed     Text format    


  22. TAKEI A, Sakamoto S, Wakai K, Tamura T, et al
    Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.
    Int J Urol. 2018 Jan 11. doi: 10.1111/iju.13521.
    PubMed     Text format     Abstract available


  23. MURATA Y, Tatsugami K, Yoshikawa M, Hamaguchi M, et al
    Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer.
    Int J Urol. 2018 Jan 8. doi: 10.1111/iju.13514.
    PubMed     Text format     Abstract available


    December 2017
  24. KOMURA K, Sweeney CJ, Inamoto T, Ibuki N, et al
    Current treatment strategies for advanced prostate cancer.
    Int J Urol. 2017 Dec 20. doi: 10.1111/iju.13512.
    PubMed     Text format     Abstract available


  25. NEUPANE S, Steyerberg E, Raitanen J, Talala K, et al
    Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
    Int J Urol. 2017 Dec 10. doi: 10.1111/iju.13508.
    PubMed     Text format     Abstract available


    November 2017
  26. NAKANO M, Araki H, Ohtakara K, Tanaka H, et al
    Significance of total colonoscopy screening before definitive radiotherapy for prostate cancer on the detection of anorectocolonic disease requiring intervention in advance.
    Int J Urol. 2017 Nov 23. doi: 10.1111/iju.13494.
    PubMed     Text format    


    October 2017
  27. YANO A, Kagawa M, Takeshita H, Okada Y, et al
    Improved survival of men with metastatic prostate cancer treated with androgen deprivation therapy plus radiotherapy to the prostate.
    Int J Urol. 2017 Oct 23. doi: 10.1111/iju.13479.
    PubMed     Text format    


  28. MITSUZUKA K, Arai Y
    Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
    Int J Urol. 2017 Oct 20. doi: 10.1111/iju.13473.
    PubMed     Text format     Abstract available


    September 2017
  29. SAIKA T, Miura N, Fukumoto T, Yanagihara Y, et al
    Role of robot-assisted radical prostatectomy in locally advanced prostate cancer.
    Int J Urol. 2017 Sep 13. doi: 10.1111/iju.13441.
    PubMed     Text format     Abstract available


  30. PEREIRA-AZEVEDO N, Braga I, Verbeek JF, Osorio L, et al
    Prospective evaluation on the effect of interobserver variability of digital rectal examination on the performance of the Rotterdam Prostate Cancer Risk Calculator.
    Int J Urol. 2017 Sep 13. doi: 10.1111/iju.13442.
    PubMed     Text format     Abstract available


  31. YANO A, Kagawa M, Takeshita H, Okada Y, et al
    Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naive prostate cancer with skeletal metastases.
    Int J Urol. 2017 Sep 11. doi: 10.1111/iju.13445.
    PubMed     Text format    


    August 2017
  32. SAKAMOTO S
    Editorial Comment to Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).
    Int J Urol. 2017 Aug 20. doi: 10.1111/iju.13436.
    PubMed     Text format    


  33. SAKAMOTO S
    Editorial Comment to Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer.
    Int J Urol. 2017 Aug 6. doi: 10.1111/iju.13433.
    PubMed     Text format    


    July 2017
  34. DINH KT, Yang DD, Nead KT, Reznor G, et al
    Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer.
    Int J Urol. 2017 Jul 22. doi: 10.1111/iju.13409.
    PubMed     Text format     Abstract available


  35. KAKEHI Y, Sugimoto M, Taoka R
    Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).
    Int J Urol. 2017 Jul 1. doi: 10.1111/iju.13380.
    PubMed     Text format     Abstract available


    June 2017
  36. NOGUCHI M, Koga N, Igawa T, Itoh K, et al
    Clinical development of immunotherapy for prostate cancer.
    Int J Urol. 2017 Jun 21. doi: 10.1111/iju.13397.
    PubMed     Text format     Abstract available


  37. MCGINLEY KF, Sun X, Howard LE, Aronson WJ, et al
    Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.
    Int J Urol. 2017 Jun 6. doi: 10.1111/iju.13387.
    PubMed     Text format     Abstract available


  38. MIZOKAMI A, Kadono Y, Kitagawa Y, Izumi K, et al
    Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
    Int J Urol. 2017 Jun 3. doi: 10.1111/iju.13372.
    PubMed     Text format     Abstract available


    May 2017
  39. ENATSU N
    Editorial Comment to Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Impl
    Int J Urol. 2017 May 31. doi: 10.1111/iju.13383.
    PubMed     Text format    


  40. NAKAJIMA K, Edenbrandt L, Mizokami A
    Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer.
    Int J Urol. 2017 May 26. doi: 10.1111/iju.13386.
    PubMed     Text format     Abstract available


  41. MITSUZUKA K
    Editorial comment to Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Int J Urol. 2017 May 21. doi: 10.1111/iju.13379.
    PubMed     Text format    


    April 2017
  42. TERADA N, Maughan BL, Akamatsu S, Kobayashi T, et al
    Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Int J Urol. 2017 Apr 28. doi: 10.1111/iju.13346.
    PubMed     Text format     Abstract available


  43. OKIHARA K, Yorozu A, Saito S, Tanaka N, et al
    Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database.
    Int J Urol. 2017 Apr 28. doi: 10.1111/iju.13358.
    PubMed     Text format     Abstract available


    March 2017
  44. NARAYAN VM, Konety BR, Warlick C
    Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
    Int J Urol. 2017 Mar 27. doi: 10.1111/iju.13326.
    PubMed     Text format     Abstract available


    February 2017
  45. SHOJI S, Hiraiwa S, Ogawa T, Kawakami M, et al
    Accuracy of real-time magnetic resonance imaging-transrectal ultrasound fusion image-guided transperineal target biopsy with needle tracking with a mechanical position-encoded stepper in detecting significant prostate cancer in biopsy-naive men.
    Int J Urol. 2017 Feb 21. doi: 10.1111/iju.13306.
    PubMed     Text format     Abstract available


  46. EGEVAD L, Samaratunga H, Delahunt B
    Editorial Comment to Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.
    Int J Urol. 2017 Feb 17. doi: 10.1111/iju.13305.
    PubMed     Text format    


  47. ALBERTS AR, Bokhorst LP, Kweldam CF, Schoots IG, et al
    Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.
    Int J Urol. 2017 Feb 7. doi: 10.1111/iju.13294.
    PubMed     Text format     Abstract available


    January 2017
  48. KESCH C, Hadaschik BA, Radtke JP
    Editorial Comment to Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology.
    Int J Urol. 2017 Jan 13. doi: 10.1111/iju.13263.
    PubMed     Text format    


    December 2016
  49. FENG T, Howard LE, Vidal AC, Moreira DM, et al
    Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study.
    Int J Urol. 2016 Dec 22. doi: 10.1111/iju.13265.
    PubMed     Text format     Abstract available


    November 2016
  50. JAZAYERI SB, Samadi DB
    Prostate cancer in African Americans: Early oncological and functional outcomes after robotic prostatectomy.
    Int J Urol. 2016 Nov 16. doi: 10.1111/iju.13255.
    PubMed     Text format    


  51. TSIVIAN M, Gupta RT, Tsivian E, Qi P, et al
    Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology.
    Int J Urol. 2016 Nov 8. doi: 10.1111/iju.13251.
    PubMed     Text format     Abstract available


    October 2016
  52. RAMALINGAM S, Eisenberg A, Foo WC, Freedman J, et al
    Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.
    Int J Urol. 2016 Oct 21. doi: 10.1111/iju.13225.
    PubMed     Text format     Abstract available


  53. KRETSCHMER A, Gratzke C
    Editorial Comment to Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.
    Int J Urol. 2016 Oct 18. doi: 10.1111/iju.13239.
    PubMed     Text format    


  54. HENNING JD, Bonachea LA, Bunker CH, Patrick AL, et al
    Human herpesvirus 8 infection contributes to a T helper 2 immune response in men from Tobago with prostate cancer.
    Int J Urol. 2016 Oct 12. doi: 10.1111/iju.13243.
    PubMed     Text format     Abstract available


    September 2016
  55. OSAWA T, Wittmann D, Jimbo M, Keller ET, et al
    Providing prostate cancer survivorship care in Japan: Implications from the USA care model.
    Int J Urol. 2016 Sep 13. doi: 10.1111/iju.13186.
    PubMed     Text format     Abstract available


  56. SCHIAVINA R, Bianchi L, Borghesi M, Briganti A, et al
    Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-institutional database.
    Int J Urol. 2016 Sep 12. doi: 10.1111/iju.13203.
    PubMed     Text format     Abstract available


    July 2016
  57. LIU CM, Hsieh CL, Shen CN, Lin CC, et al
    Exosomes from the tumor microenvironment as reciprocal regulators that enhance prostate cancer progression.
    Int J Urol. 2016 Jul 10. doi: 10.1111/iju.13145.
    PubMed     Text format     Abstract available


    June 2016
  58. PARIMI S, Chi KN
    Chemotherapy for metastatic castration-sensitive prostate cancer.
    Int J Urol. 2016 Jun 26. doi: 10.1111/iju.13148.
    PubMed     Text format     Abstract available


  59. SAKAMOTO S
    Editorial Comment to Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
    Int J Urol. 2016 Jun 20. doi: 10.1111/iju.13147.
    PubMed     Text format    


  60. SAKAMOTO S
    Editorial Comment to Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
    Int J Urol. 2016 Jun 20. doi: 10.1111/iju.13146.
    PubMed     Text format    


  61. IMAMURA Y, Sadar MD
    Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
    Int J Urol. 2016 Jun 14. doi: 10.1111/iju.13137.
    PubMed     Text format     Abstract available


  62. PORPIGLIA F, Cantiello F, De Luca S, De Pascale A, et al
    Multiparametric magnetic resonance imaging and active surveillance: How to better select insignificant prostate cancer?
    Int J Urol. 2016 Jun 9. doi: 10.1111/iju.13138.
    PubMed     Text format     Abstract available


  63. BRYCE AH, Antonarakis ES
    Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
    Int J Urol. 2016 Jun 3. doi: 10.1111/iju.13134.
    PubMed     Text format     Abstract available


    May 2016
  64. UENO Y, Tamada T, Bist V, Reinhold C, et al
    Multiparametric magnetic resonance imaging: Current role in prostate cancer management.
    Int J Urol. 2016 May 17. doi: 10.1111/iju.13119.
    PubMed     Text format     Abstract available


    April 2016
  65. SAKAMOTO S
    Editorial Comment to Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Int J Urol. 2016 Apr 17. doi: 10.1111/iju.13090.
    PubMed     Text format    


  66. SHIOTA M, Eto M
    Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Int J Urol. 2016 Apr 8. doi: 10.1111/iju.13091.
    PubMed     Text format     Abstract available


  67. MITSUZUKA K
    Editorial Comment to Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients.
    Int J Urol. 2016;23:317-8.
    PubMed     Text format    


  68. IREMASHVILI V, Barney SL, Manoharan M, Kava BR, et al
    Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients.
    Int J Urol. 2016;23:313-7.
    PubMed     Text format     Abstract available


    March 2016
  69. KIMURA G, Yonese J, Fukagai T, Kamba T, et al
    Enzalutamide in Japanese patients with chemotherapy-naive, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.
    Int J Urol. 2016 Mar 27. doi: 10.1111/iju.13072.
    PubMed     Text format     Abstract available


  70. MCGINLEY KF, Sun X, Howard LE, Aronson WJ, et al
    Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database.
    Int J Urol. 2016;23:241-6.
    PubMed     Text format     Abstract available


    February 2016
  71. SUN Y, Zou Q, Sun Z, Li C, et al
    Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
    Int J Urol. 2016 Feb 15. doi: 10.1111/iju.13051.
    PubMed     Text format     Abstract available


  72. BIRKELAND S
    Re: Prostate-specific antigen-based prostate cancer screening: Past and future.
    Int J Urol. 2016 Feb 2. doi: 10.1111/iju.13038.
    PubMed     Text format    


    January 2016
  73. GANDAGLIA G, Montorsi F, Briganti A
    Editorial Comment to Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.
    Int J Urol. 2016 Jan 20. doi: 10.1111/iju.13046.
    PubMed     Text format    


  74. SCHMID M, Hanske J, Ravi P, Krishna N, et al
    Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.
    Int J Urol. 2016 Jan 13. doi: 10.1111/iju.13043.
    PubMed     Text format     Abstract available


  75. SONG W, Jeon HG, Sung HH, Jeong BC, et al
    Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.
    Int J Urol. 2016;23:56-61.
    PubMed     Text format     Abstract available


    December 2015
  76. MATSUSHIMA M, Kikuchi E, Matsumoto K, Kosaka T, et al
    Erectile function status is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy.
    Int J Urol. 2015 Dec 12. doi: 10.1111/iju.13029.
    PubMed     Text format     Abstract available


    November 2015
  77. ROMERO-OTERO J, Garcia-Gomez B, Duarte-Ojeda JM, Rodriguez-Antolin A, et al
    Active surveillance for prostate cancer.
    Int J Urol. 2015 Nov 30. doi: 10.1111/iju.13016.
    PubMed     Text format     Abstract available


    August 2015
  78. HISASUE SI
    Contemporary perspective and management of testosterone deficiency: Modifiable factors and variable management.
    Int J Urol. 2015 Aug 25. doi: 10.1111/iju.12880.
    PubMed     Text format     Abstract available


    May 2015
  79. SCHIFFMANN J, Beyer B, Tennstedt P, Boehm K, et al
    Oncological outcome after radical prostatectomy: Marital status does not make a difference.
    Int J Urol. 2015;22:484-9.
    PubMed     Text format     Abstract available


  80. SKARECKY D
    Editorial Comment from Mr Skarecky to Comparative investigation on clinical outcomes of robot-assisted radical prostatectomy between experienced open prostatic surgeons and novice open surgeons in a laparoscopically naive center with a limited caseloa
    Int J Urol. 2015;22:476.
    PubMed     Text format    


  81. SHIROKI R
    Editorial Comment from Dr Shiroki to Comparative investigation on clinical outcomes of robot-assisted radical prostatectomy between experienced open prostatic surgeons and novice open surgeons in a laparoscopically naive center with a limited caseload
    Int J Urol. 2015;22:475.
    PubMed     Text format    


  82. SUMITOMO M, Kanao K, Kato Y, Yoshizawa T, et al
    Comparative investigation on clinical outcomes of robot-assisted radical prostatectomy between experienced open prostatic surgeons and novice open surgeons in a laparoscopically naive center with a limited caseload.
    Int J Urol. 2015;22:469-74.
    PubMed     Text format     Abstract available


    April 2015
  83. SATO YT
    Editorial comment to Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital d
    Int J Urol. 2015;22:366-7.
    PubMed     Text format    


  84. MITHAL P, Howard LE, Aronson WJ, Kane CJ, et al
    Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Int J Urol. 2015;22:362-6.
    PubMed     Text format     Abstract available


    March 2015
  85. ROEHRBORN CG, Casabe A, Glina S, Sorsaburu S, et al
    Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study compari
    Int J Urol. 2015 Mar 31. doi: 10.1111/iju.12741.
    PubMed     Text format     Abstract available


  86. ETO M
    IJU this issue.
    Int J Urol. 2015;22:241.
    PubMed     Text format    


  87. NAMIKI S
    Editorial comment to International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy.
    Int J Urol. 2015;22:287.
    PubMed     Text format    


  88. BAYOUD Y, de la Taille A, Ouzzane A, Ploussard G, et al
    International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy.
    Int J Urol. 2015;22:283-7.
    PubMed     Text format     Abstract available


  89. YUMIOKA T, Iwamoto H, Masago T, Morizane S, et al
    Robot-assisted radical prostatectomy in an initial Japanese series: the impact of prior abdominal surgery on surgical outcomes.
    Int J Urol. 2015;22:278-82.
    PubMed     Text format     Abstract available


  90. MATSUYAMA H, Matsumoto H, Nagao K, Harada N, et al
    Running suture versus interrupted suture for vesicourethral anastomosis in retropubic radical prostatectomy: a randomized study.
    Int J Urol. 2015;22:271-7.
    PubMed     Text format     Abstract available


    February 2015
  91. EGAWA S
    IJU this issue.
    Int J Urol. 2015;22:139.
    PubMed     Text format    


  92. SIVARAMAN A, Sanchez-Salas R, Barret E, Ahallal Y, et al
    Transperineal template-guided mapping biopsy of the prostate.
    Int J Urol. 2015;22:146-51.
    PubMed     Text format     Abstract available


  93. TSUZUKI T
    Intraductal carcinoma of the prostate: a comprehensive and updated review.
    Int J Urol. 2015;22:140-5.
    PubMed     Text format     Abstract available


  94. HASHIMOTO T, Yoshioka K, Nagao G, Nakagami Y, et al
    Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.
    Int J Urol. 2015;22:188-93.
    PubMed     Text format     Abstract available


  95. SHOJI S, Hiraiwa S, Endo J, Hashida K, et al
    Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience.
    Int J Urol. 2015;22:173-8.
    PubMed     Text format     Abstract available


  96. SHOJI S
    Response to editorial comment to Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience.
    Int J Urol. 2015;22:179-80.
    PubMed     Text format    


  97. TELONIS D, Mouraviev V
    Editorial comment to Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience.
    Int J Urol. 2015;22:178-9.
    PubMed     Text format    


  98. SHIMBO M
    Editorial comment to Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.
    Int J Urol. 2015;22:193-4.
    PubMed     Text format    


  99. MITSUZUKA K
    Editorial comment to Transperineal template-guided mapping biopsy of the prostate.
    Int J Urol. 2015;22:152.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: